 | |
| Clinical data | |
|---|---|
| Other names | N-[2-(Trifluoromethyl)phenyl]-3-oxo-4-aza-4-methyl-5α-androst-1-en-17α-carboxamide |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C27H33F3N2O2 |
| Molar mass | 474.568 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TFM-4AS-1 is a dualselective androgen receptor modulator (SARM) and5α-reductase inhibitor.[1][2] It is a potent andselectivepartial agonist (Emax = 55%) of theandrogen receptor (IC50 = 30 nM) andinhibitor of5α-reductasetypes I andII (IC50 = 2 and 3 nM, respectively).[1][2] TFM-4AS-1 showstissue-selectiveandrogenic effects; it promotes the accumulation ofbone andmuscle mass and has reduced effects inreproductive tissues andsebaceous glands.[2] In an animal study, TFM-4AS-1 stimulated sebaceous gland formation only 31% as much asdihydrotestosterone (DHT) at doses that were as anabolic or more so than DHT.[3][2] In addition, TFM-4AS-1 only weakly promoted growth of the prostate gland and itpartially antagonized the actions of DHT in the seminal vesicles and endogenous androgens in the prostate gland.[2] Structurally, TFM-4AS-1 is a4-azasteroid.[1] A structurally related and more advanced version of TFM-4AS-1,MK-0773, was developed and pursued for potential pharmaceutical use.[3]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
